Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting
December 02, 2021 08:00 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
November 04, 2021 16:15 ET
|
Aprea Therapeutics
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
November 04, 2021 09:17 ET
|
Imara, Inc.
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
November 04, 2021 09:07 ET
|
Sana Biotechnology, Inc
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
Immunicum presenterar uppdaterade resultat för Fas II ADVANCE II vid Annual American Society of Hematology Meeting (ASH)
November 04, 2021 09:02 ET
|
Immunicum AB
Pressmeddelande 4 november 2021 Immunicum presenterar uppdaterade resultat för Fas II ADVANCE II vid Annual American Society of Hematology Meeting (ASH) Immunicum AB (publ; IMMU.ST), ett...
Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)
November 04, 2021 09:02 ET
|
Immunicum AB
Press Release November 4, 2021 Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH) Immunicum AB (publ; IMMU.ST), a biopharmaceutical...
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
December 07, 2020 07:30 ET
|
MacroGenics, Inc.
53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD, Dec. 07,...
Aptose Presents Highlights from ASH and Corporate Update Event
December 06, 2020 17:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
December 06, 2020 13:00 ET
|
MacroGenics, Inc.
31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc....
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
December 05, 2020 17:00 ET
|
Cellectis Inc.
Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease 2 out of 3 Patients at DL1 Achieved...